In this Q&A, Dr. Luis E. Raez and nurse practitioner Beth Sandy discuss recently reported MARIPOSA data in the context of current standard of care and provide best practices for therapeutic selection and patient education. Read more
Dr. Hidehito Horinouchi said treatment with Teliso-V demonstrated promising and durable responses in Asian cohort, particularly those with high c-Met expression. Read more
Dr. Jacob Sands presented findings that show a progression-free survival advantage for Dato-DXd versus docetaxel in the non-squamous cohort. Read more
The session will also include late-breaking data from HARMONi-2, NeoCOAST-2, and TROPION-Lung01 as well as an address from IASLC President Dr. Paul Van Schil. Read more
Drs. Jyoti Patel and Khyati Somayaji Dasika say the increased burden of lung cancer on women underscores the necessity for gender-sensitive approaches in healthcare policy, research, and clinical practice. Read more
While the study did not meet its primary endpoint of overall survival, it did demonstrate a significant benefit in overall and progression-free survival in the non-epithelioid patient population. Read more
In an interview with ILCN, principal investigator Dr. Jeffrey Bradley discusses his thoughts on why the trial proved negative. Read more
Dr. Anne-Marie C. Dingemans said the data indicate that it is safe to prescribe tarlatamab for these patients now that it has been approved by the US FDA. Read more
Presenter Dr. Bob T. Li said further study is needed, particularly given the positive PFS results in PDL-1-negative patients, who represent an unmet medical need. Read more
However, Drs. Marthe S. Paats and Anne-Marie C. Dingemans caution that in the light of the toxicity profile, the combination may not be the best option for all patients. Read more
When presenting the data, Dr. Benjamin Solomon said first-line lorlatinib offers unprecedented improvement in outcomes for patients with advanced ALK+ non-small cell lung cancer. Read more